172 related articles for article (PubMed ID: 26484408)
1. SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?
Bloomgarden ZT; Handelsman Y
Endocr Pract; 2015 Dec; 21(12):1442-4. PubMed ID: 26484408
[No Abstract] [Full Text] [Related]
2. SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.
Saroka RM; Kane MP; Busch RS; Watsky J; Hamilton RA
Endocr Pract; 2015 Dec; 21(12):1315-22. PubMed ID: 26307900
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on Canagliflozin 300: review of its efficacy and an indirect comparison to other SGLT-2 inhibitors and long-acting GLP-1 receptor agonists.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):633-647. PubMed ID: 28393583
[TBL] [Abstract][Full Text] [Related]
4. The effect of combined treatment with canagliflozin and teneligliptin on glucose intolerance in Zucker diabetic fatty rats.
Oguma T; Kuriyama C; Nakayama K; Matsushita Y; Yoshida K; Kiuchi S; Ikenaga Y; Nakamaru Y; Hikida K; Saito A; Arakawa K; Oka K; Ueta K; Shiotani M
J Pharmacol Sci; 2015 Apr; 127(4):456-61. PubMed ID: 25892328
[TBL] [Abstract][Full Text] [Related]
5. [Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
Gallwitz B
MMW Fortschr Med; 2010 May; 152(20):43-4. PubMed ID: 20552881
[No Abstract] [Full Text] [Related]
6. Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience.
Deol H; Lekkakou L; Viswanath AK; Pappachan JM
Endocrine; 2017 Jan; 55(1):173-178. PubMed ID: 27696231
[TBL] [Abstract][Full Text] [Related]
7. Fracture Risk After Initiation of Use of Canagliflozin: A Cohort Study.
Fralick M; Kim SC; Schneeweiss S; Kim D; Redelmeier DA; Patorno E
Ann Intern Med; 2019 Feb; 170(3):155-163. PubMed ID: 30597484
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 agonists and SGLT-2 inhibitors in adults with sickle cell disease.
Sun R; Srivastava A; Derebail VK; Han J; Molokie RE; Gordeuk V; Saraf SL
Am J Hematol; 2024 Aug; 99(8):1610-1612. PubMed ID: 38655752
[No Abstract] [Full Text] [Related]
9. Comparison of New Glucose-Lowering Drugs on Risk of Heart Failure in Type 2 Diabetes: A Network Meta-Analysis.
Kramer CK; Ye C; Campbell S; Retnakaran R
JACC Heart Fail; 2018 Oct; 6(10):823-830. PubMed ID: 30196071
[TBL] [Abstract][Full Text] [Related]
10. Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.
Okahata S; Sakamoto K; Mitsumatsu T; Kondo Y; Tanaka S; Shiba T
Diabetes Obes Metab; 2019 Feb; 21(2):388-392. PubMed ID: 30146790
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of antidiabetic drugs.
Sørensen AM; Christensen MB
Drugs Today (Barc); 2018 Sep; 54(9):547-559. PubMed ID: 30303495
[TBL] [Abstract][Full Text] [Related]
12. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
[TBL] [Abstract][Full Text] [Related]
13. The effect of sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists on cardiovascular disease in patients with type 2 diabetes.
Dey AK; Groenendyk J; Mehta NN; Gourgari E
Clin Cardiol; 2019 Mar; 42(3):406-412. PubMed ID: 30635924
[TBL] [Abstract][Full Text] [Related]
14. Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: Sequential or simultaneous start?
Goncalves E; Bell DSH
Diabetes Obes Metab; 2017 Jun; 19(6):909-911. PubMed ID: 28176440
[No Abstract] [Full Text] [Related]
15. In brief: Canagliflozin and lower limb amputations.
Med Lett Drugs Ther; 2020 Sep; 62(1607):152. PubMed ID: 32960870
[No Abstract] [Full Text] [Related]
16. The Effect of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter-2 Inhibitors in Patients Prescribed Regular U-500 Insulin.
Meade LT; Mannka ML
Ann Pharmacother; 2019 Nov; 53(11):1111-1116. PubMed ID: 31215219
[No Abstract] [Full Text] [Related]
17. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
[TBL] [Abstract][Full Text] [Related]
18. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study.
Dave CV; Schneeweiss S; Kim D; Fralick M; Tong A; Patorno E
Ann Intern Med; 2019 Aug; 171(4):248-256. PubMed ID: 31357213
[TBL] [Abstract][Full Text] [Related]
19. Effect of canagliflozin on circulating active GLP-1 levels in patients with type 2 diabetes: a randomized trial.
Takebayashi K; Hara K; Terasawa T; Naruse R; Suetsugu M; Tsuchiya T; Inukai T
Endocr J; 2017 Sep; 64(9):923-931. PubMed ID: 28824041
[TBL] [Abstract][Full Text] [Related]
20. Review: In type 2 diabetes, SGLT-2 inhibitors or GLP-1 agonists reduce mortality vs control or DPP-4 inhibitors.
Egan AM; Montori VM
Ann Intern Med; 2018 Jul; 169(2):JC2. PubMed ID: 30014091
[No Abstract] [Full Text] [Related]
[Next] [New Search]
